

Buy EUR 34.00	Value Indicators:	EUR	Warburg ESG Risk Score: 2.8	Description: Mutares is a PE group which specializes on turnaround and restructuring cases
	SotP:	33.67	ESG Score (MSCI based): 3.0	
Price	EUR 22.75		Balance Sheet Score: 3.3	
Upside	49.5 %		Market Liquidity Score: 2.0	
Market Snapshot:		EUR m	Shareholders:	Key Figures (WRe):
Market cap:	468		Freefloat	2023e
No. of shares (m):	21		Robin Laik (CEO)	Beta:
EV:	1,050		Elber GmbH	Price / Book:
Freefloat MC:	304			Equity Ratio:
Ø Trad. Vol. (30d):	519.94 th			Net Fin. Debt / EBITDA:
				Net Debt / EBITDA:

First Glance: Q2 shows strong operational improvement; Exits ahead

	Q2 23 A	Q2 22 A	yoy	Q1 23 A	qoq
Sales Holding	25,0	14,0	79%	27,1	-8%
Portfolio Income	25,0	17,9	40%	27,1	-8%
EBITDA Holding	3,4	4,3	-21%	9,5	-64%
Net income Holding	5,2	7,5	-31%	8,2	-37%
Sales Group	1.165,6	902	29%	1.108,0	5%
Adj. EBITDA Group	36,1	-2,2	n.m.	5,1	n.m.
Sales Realignment	497,7	338,5	47%	476,4	4%
Adj. EBITDA Realignment	16,3	-13,4	n.m.	-19,8	n.m.
Sales Optimization	482	314,7	53%	395,2	22%
Adj. EBITDA Optimization	4,3	-5,6	n.m.	-1,0	n.m.
Sales Harvesting	186,6	249,7	-25%	237,1	-21%
Adj. EBITDA Harvesting	7,7	14,9	-48%	17,1	-55%


Mutares posted a strong operational result in Q2 with 3.0% adj. EBITDA margin and positive adj. EBITDA contributions even in the Realignment group, which deals with the recently acquired companies that undergo restructuring. Looking into the industry segments, the major swing occurred in the automotive segment, which turned a c. EUR 18m adj. EBITDA loss into a profit of the same magnitude yoy. SCF, which is part of the newly founded Amaneos was a strong contributor here. The goods and services segment also showed sound improvement. Q2 saw the closing of Peugeot Motorcycle and Arriva as major transactions on the buy side, leading to bargain purchases of more than EUR 250m.

Even though Q2 sales at Holding level were a bit lower than Q1, we are still on a run rate for more than EUR 100m in FY 23 and a significant growth rate yoy. In H1, no equity dividends were booked, leading to a portfolio income in the amount of Holding sales.

The SMP exit is still pending and depends on a decision by the UK regulator. Closing is expected in Q3. As well as SMP, management indicated that Frigoscandia is possibly moving for an exit but it eventually stepped away from the process at La Rochette. While a finalization of SMP will most likely lead to a beat of the current Holding net income guidance giving the selling price of up to EUR 150m, the guidance was left unchanged for the time being.

As well as the acquisition of Selzer from Indus, Mutares signed a deal to acquire CEI Forging Germany and indicated a further project in the pipeline with c. EUR 150m in annualized sales that would be integrated into the newly formed Ferr/Al United (former Metals Group). The group would generate annualized sales of more than EUR 1.3bn with 25 production locations in the US, EU and Asia. After Amaneos, this would be the next formation for a possible IPO in the medium term.

Mutares opened a Chinese subsidiary and views the global near-shoring process as a major business opportunity. Chinese companies selling overseas assets which could be acquired as an add-on, or foreign corporates selling the Chinese business would be the major target.




Rel. Performance vs CDAX:	
1 month:	-5.2 %
6 months:	10.7 %
Year to date:	15.0 %
Trailing 12 months:	10.7 %

Company events:	
07.11.23	Q3


FY End: 31.12. in EUR m	CAGR (22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
Sales	14.3 %	1,016	1,584	2,504	3,752	5,089	5,490	5,595
Change Sales yoy		17.4 %	55.9 %	58.1 %	49.8 %	35.6 %	7.9 %	1.9 %
Sales Holding	26.7 %	19	32	50	71	109	130	145
Chg yoy		83.0 %	65.0 %	58.2 %	40.9 %	53.6 %	18.6 %	11.8 %
Portfolio equity distributions		22	35	14	69	22	37	55
Portfolio income		41	66	65	140	131	167	200
Exit gains	-	0	0	58	4	114	0	0
Net income holding		23	33	50	71	125	44	69
Net income margin holding		116.6 %	104.7 %	98.2 %	100.3 %	114.8 %	34.0 %	47.5 %
EBITDA adj.		7	-29	-41	-33	71	168	243
Net income	-	21	27	449	-7	-50	-69	2
Net income adj.		23	33	50	71	125	44	69
EPS adj.		1.48	2.20	3.00	3.46	6.08	2.13	3.33
P / E adj.		6.8 x	5.1 x	7.4 x	5.6 x	3.7 x	10.7 x	7.1 x
DPS	0.0 %	1.00	1.50	1.50	2.00	2.00	2.00	2.00
Dividend Yield		10.0 %	13.3 %	6.8 %	10.4 %	8.8 %	8.8 %	8.5 %
EPS		1.37	1.79	27.18	-0.33	-2.43	-3.35	0.12
P / E		7.3 x	6.3 x	0.8 x	n.a.	n.a.	n.a.	196.7 x
Guidance:		Group sales EUR 4.8-5.4bn, net income holding EUR 92-112m						

Sales development
in EUR m




Source: Warburg Research

Sales by cycle phase
2022; in %



Source: Warburg Research

Sales by segment
2022; %



Source: Warburg Research


Company Background

- Mutares was co-founded in 2008 by CEO Robin Laik.
- Mutares invests in small/midcap (sales 50-500m) companies in special situations and manages the turnaround with its own consultants
- Consolidated sales increased from EUR 60m in 2010 to above EUR 2.5bn in 2021 as the company made more than 80 transactions
- Mutares has consistently paid a dividend and targets a base dividend of EUR 1.0. The dividend yield has exceeded 5% over the past five years.
- The company issued a bond and raised equity of combind 180m in the last two years to accelerate growth as the Covid pandemic gave rise to unique investment opportunities

Competitive Quality


- With more than 100consultants, who are turnaround specialists, at the end of 2020, Mutares has established a European network of offices enabling the generation of synergies across its portfolio holdings.
- European small-midcap special situations management is a niche market with limited competition
- Management and board members hold significant stakes of outstanding shares
- For FY 23 Mutares targets annual consolidated sales of EUR 5bn, which translates into a holding profit of EUR 100m respectively a net margin of 1.8-2.2%

Sales Mutares Holding
in EUR m



Source: Warburg Research

Net income development
in EUR m



Source: Warburg Research

Valuation

Net Asset Value		all Warburg Research estimates						
Company	exit date	sales Wre	EBITDA margin	EBITDA / EBIT	Exit mutiple	EV	probability	NPV
Amaneos	2026	1.200	6%	72,0	6,0	432	25%	81,4
Arriva	2027	400	7%	28,0	6,0	168	10%	11,5
Asteri / Palmia	2026	150	5%	7,5	6,0	45	10%	3,4
Celcim	2026	55	9%	5,0	7,0	35	35%	9,1
Donges Group	2023	200	8%	16,0	7,0	112	35%	39,2
Exi / Six	2026	75	6%	4,5	8,0	36	25%	6,8
Fasana	2026	65	7%	4,6	8,0	36	10%	2,7
Frigoscandia	2026	365	6%	21,9	7,0	153	25%	28,9
Ganter	2026	80	7%	5,6	7,0	39	25%	7,4
Gemini / Adcoms	2024	100	8%	8,0	8,0	64	10%	5,8
Guascor Energy	2027	100	8%	8,0	7,0	56	10%	3,8
iinovis group (Valmet Automotive)	2026	50	5%	2,5	5,0	13	10%	0,9
keeper	2024	90	11%	9,9	9,0	89	25%	20,3
Kico Group	2026	220	10%	22,0	6,0	132	25%	24,9
La Rochette	2026	160	9%	14,4	7,0	101	35%	26,6
Lapyere	2026	750	8%	60,0	7,0	570	10%	42,9
Metals Group	2027	600	8%	48,0	7,0	336	10%	23,0
NEM/Balcke-Dürr	2026	340	6%	20,4	6,0	122	25%	23,0
Peugeot Motor	2028	140	7%	9,8	6,0	59	10%	1,8
Plati	2026	40	8%	3,0	7,0	21	25%	4,0
Repartim (Carglas Maison)	2026	40	7%	2,8	7,0	20	25%	3,0
Sabo	2026	30	10%	3,0	8,0	24	50%	9,0
SMP (Special melted products)	2023	140	9%	12,6	7,0	88	10%	150,0
Steyr Motors	2026	30	7%	2,1	7,0	15	10%	1,1
Terranor (Nordic Road Services)	2024	215	9%	19,4	7,0	135	35%	43,1
VALTI (Vallourec Bearing Tubes)	2027	50	7%	3,5	7,0	25	10%	1,7
Walor	2027	200	8%	16,0	6,0	96	10%	6,6
						2493,6		563,9

	2022	2023e	2024e	2025e
Sum of the Parts (EURm)				
Consulting revenues	71,1	109,2	129,5	144,8
Consulting profit (EBITDA)	13,2	19,7	23,3	26,1
WACC				9,9%
			TV	263
Equity distributions	69	22,0	37,0	55,0
WACC				9,9%
			TV	555
(+) NPV portfolio		564		
(-) Discounted TV equity distributions		460		
NPV portfolio surplus		104,2		

Enterprise Value / CF	145,9	60,3	818,3
Discounted values	145,9	54,9	677,4
Discounted sum EV/CF	878,2		
Debt	100,0		
Cash	12,5		
Other debt like items	98,3		
Equity Value	692		
Number of shares outstanding	20,6		
Fair value per share (EUR)	33,7		

Valuation	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	0.8 x	0.9 x	0.5 x	0.6 x	0.6 x	0.6 x	0.6 x
Book value per share ex intangibles	8.17	7.38	28.56	27.56	33.31	30.38	30.92
EV / Sales	0.4 x	0.3 x	0.3 x	0.3 x	0.2 x	0.2 x	0.2 x
EV / EBITDA	4.6 x	3.6 x	1.5 x	6.0 x	6.2 x	6.4 x	4.2 x
EV / EBIT	14.0 x	12.5 x	2.0 x	n.a.	n.a.	n.a.	52.3 x
EV / EBIT adj.*	14.0 x	n.a.	n.a.	7.8 x	n.a.	n.a.	52.3 x
P / FCF	n.a.	n.a.	n.a.	n.a.	n.a.	23.0 x	4.2 x
P / E	7.3 x	6.3 x	0.8 x	n.a.	n.a.	n.a.	196.7 x
P / E adj.*	6.8 x	5.1 x	7.4 x	5.6 x	3.7 x	10.7 x	7.1 x
Dividend Yield	10.0 %	13.3 %	6.8 %	10.4 %	8.8 %	8.8 %	8.5 %
FCF Potential Yield (on market EV)	21.5 %	28.2 %	66.4 %	20.0 %	16.2 %	15.6 %	23.9 %

*Adjustments made for: -

Company Specific Items	2019	2020	2021	2022	2023e	2024e	2025e
Sales Holding	19	32	50	71	109	130	145
Portfolio equity distributions	22	35	14	69	22	37	55
Exit gains	0	0	58	4	114	0	0
Net income holding	23	33	50	71	125	44	69
adj. EBITDA holding	1	5	-18	-7	2	21	29
Income investments holding	22	35	71	72	136	37	55
Chg yoy	83.0 %	65.0 %	58.2 %	40.9 %	53.6 %	18.6 %	11.8 %
Net income margin holding	116.6 %	104.7 %	98.2 %	100.3 %	114.8 %	34.0 %	47.5 %
Consulting income	-1	4	7	13	20	23	26
Portfolio income	41	66	65	140	131	167	200

Consolidated profit & loss

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Sales	1,016	1,584	2,504	3,752	5,089	5,490	5,595
Change Sales yoy	17.4 %	55.9 %	58.1 %	49.8 %	35.6 %	7.9 %	1.9 %
Increase / decrease in inventory	-4	-23	7	-16	0	0	0
Total Sales	1,012	1,561	2,511	3,735	5,089	5,490	5,595
Material expenses	623	975	1,580	2,399	3,257	3,514	3,581
Gross profit	389	586	931	1,337	1,832	1,977	2,014
<i>Gross profit margin</i>	<i>38.3 %</i>	<i>37.0 %</i>	<i>37.2 %</i>	<i>35.6 %</i>	<i>36.0 %</i>	<i>36.0 %</i>	<i>36.0 %</i>
Personnel expenses	292	424	660	910	1,476	1,592	1,623
Other operating income	119	241	770	356	597	644	656
Other operating expenses	138	261	474	601	782	860	804
Unfrequent items	0	0	0	0	0	0	0
EBITDA	79	143	567	181	171	168	243
<i>Margin</i>	<i>7.8 %</i>	<i>9.0 %</i>	<i>22.6 %</i>	<i>4.8 %</i>	<i>3.4 %</i>	<i>3.1 %</i>	<i>4.3 %</i>
Depreciation of fixed assets	53	102	119	185	204	220	224
EBITA	26	41	448	-3	-33	-52	19
Amortisation of intangible assets	0	0	0	0	0	0	0
Goodwill amortisation	0	0	0	0	0	0	0
EBIT	26	41	448	-3	-33	-52	19
<i>Margin</i>	<i>2.6 %</i>	<i>2.6 %</i>	<i>17.9 %</i>	<i>-0.1 %</i>	<i>-0.6 %</i>	<i>-0.9 %</i>	<i>0.3 %</i>
EBIT adj.	26	-130	-160	140	-33	-52	19
Interest income	2	4	9	15	1	1	1
Interest expenses	11	28	27	68	18	18	18
Other financial income (loss)	0	0	0	0	0	0	0
EBT	17	17	429	-56	-50	-69	2
<i>Margin</i>	<i>1.6 %</i>	<i>1.1 %</i>	<i>17.1 %</i>	<i>-1.5 %</i>	<i>-1.0 %</i>	<i>-1.3 %</i>	<i>0.0 %</i>
Total taxes	0	-3	-14	-36	0	0	0
Net income from continuing operations	17	20	443	-21	-50	-69	2
Income from discontinued operations (net of tax)	0	0	0	0	0	0	0
Net income before minorities	17	20	443	-21	-50	-69	2
Minority interest	-4	-7	-7	-14	0	0	0
Net income	21	27	449	-7	-50	-69	2
<i>Margin</i>	<i>2.0 %</i>	<i>1.7 %</i>	<i>17.9 %</i>	<i>-0.2 %</i>	<i>-1.0 %</i>	<i>-1.3 %</i>	<i>0.0 %</i>
Net income adj.	23	33	50	71	125	44	69
Number of shares, average	15	15	17	21	21	21	21
EPS	1.37	1.79	27.18	-0.33	-2.43	-3.35	0.12
EPS adj.	1.48	2.20	3.00	3.46	6.08	2.13	3.33

*Adjustments made for:


Guidance: Group sales EUR 4.8-5.4bn, net income holding EUR 92-112m

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	91.8 %	89.5 %	77.6 %	94.7 %	96.6 %	96.9 %	95.7 %
Operating Leverage	2.0 x	1.0 x	17.0 x	n.a.	26.2 x	7.3 x	n.a.
EBITDA / Interest expenses	7.2 x	5.1 x	20.8 x	2.7 x	9.5 x	9.3 x	13.5 x
Tax rate (EBT)	0.0 %	-16.6 %	-3.2 %	62.8 %	0.0 %	0.0 %	0.0 %
Dividend Payout Ratio	91.2 %	115.6 %	5.6 %	n.m.	n.m.	n.m.	1684.6 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.


Sales, EBITDA

in EUR m




Operating Performance

in %



Performance per Share



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated balance sheet

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Assets							
Goodwill and other intangible assets	59	76	134	144	144	144	144
thereof other intangible assets	59	76	134	144	144	144	144
thereof Goodwill	0	0	0	0	0	0	0
Property, plant and equipment	176	243	557	764	645	510	370
Financial assets	17	9	74	46	46	46	46
Other long-term assets	123	150	324	398	398	398	398
Fixed assets	375	478	1,088	1,352	1,233	1,098	959
Inventories	134	204	423	561	727	784	799
Accounts receivable	172	295	342	458	621	670	683
Liquid assets	80	145	255	246	372	351	425
Other short-term assets	88	206	452	412	412	412	412
Current assets	474	850	1,472	1,677	2,133	2,218	2,320
Total Assets	849	1,327	2,560	3,030	3,366	3,316	3,278
Liabilities and shareholders' equity							
Subscribed capital	15	15	21	21	21	21	21
Capital reserve	37	38	134	135	135	135	135
Retained earnings	135	144	566	527	435	325	286
Other equity components	-2	-7	1	31	241	291	341
Shareholders' equity	185	190	721	713	831	771	782
Minority interest	23	17	15	1	1	1	1
Total equity	208	207	736	714	833	772	783
Provisions	138	210	326	332	262	192	122
thereof provisions for pensions and similar obligations	87	116	153	94	94	94	94
Financial liabilities (total)	208	374	610	841	860	860	860
Short-term financial liabilities	41	57	69	136	136	136	136
Accounts payable	195	319	525	754	1,022	1,103	1,124
Other liabilities	100	217	363	389	389	389	389
Liabilities	640	1,120	1,824	2,316	2,533	2,544	2,495
Total liabilities and shareholders' equity	849	1,327	2,560	3,030	3,366	3,316	3,278


Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	3.5 x	3.8 x	3.1 x	3.6 x	5.2 x	6.4 x	7.7 x
Capital Employed Turnover	2.4 x	2.9 x	2.0 x	2.7 x	3.6 x	4.0 x	4.3 x
ROA	5.5 %	5.7 %	41.3 %	-0.5 %	-4.1 %	-6.3 %	0.3 %
Return on Capital							
ROCE (NOPAT)	7.5 %	9.8 %	51.4 %	n.a.	n.a.	n.a.	1.4 %
ROE	11.4 %	14.4 %	98.6 %	-0.9 %	-6.5 %	-8.6 %	0.3 %
Adj. ROE	12.3 %	17.8 %	10.9 %	9.9 %	16.2 %	5.5 %	8.9 %
Balance sheet quality							
Net Debt	215	345	508	689	583	603	530
Net Financial Debt	128	228	355	595	488	509	435
Net Gearing	103.5 %	166.3 %	69.0 %	96.6 %	70.0 %	78.1 %	67.6 %
Net Fin. Debt / EBITDA	161.7 %	160.1 %	62.6 %	328.0 %	286.3 %	303.9 %	178.9 %
Book Value / Share	12.0	12.3	35.1	34.5	40.3	37.4	37.9
Book value per share ex intangibles	8.2	7.4	28.6	27.6	33.3	30.4	30.9


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	17	20	443	-21	-50	-69	2
Depreciation of fixed assets	53	102	119	185	204	220	224
Amortisation of goodwill	0	0	0	0	0	0	0
Amortisation of intangible assets	0	0	0	0	0	0	0
Increase/decrease in long-term provisions	-15	7	-19	-59	0	0	0
Other non-cash income and expenses	-118	-243	-705	-100	0	0	0
Cash Flow before NWC change	-63	-115	-163	5	154	151	226
Increase / decrease in inventory	20	17	-22	-138	-166	-57	-15
Increase / decrease in accounts receivable	34	7	43	-117	-163	-49	-13
Increase / decrease in accounts payable	-2	48	38	228	269	81	21
Increase / decrease in other working capital positions	0	0	0	0	-20	-20	-20
Increase / decrease in working capital (total)	53	72	59	-26	-81	-46	-27
Net cash provided by operating activities [1]	-11	-43	-104	-21	73	105	199
Investments in intangible assets	0	0	0	0	0	0	0
Investments in property, plant and equipment	0	-29	-48	-84	-84	-84	-84
Payments for acquisitions	33	79	189	110	10	0	0
Financial investments	0	1	1	2	0	0	0
Income from asset disposals	23	1	33	46	150	0	0
Net cash provided by investing activities [2]	44	51	172	73	76	-84	-84
Change in financial liabilities	0	104	236	232	19	0	0
Dividends paid	-15	-15	-25	-31	-41	-41	-41
Purchase of own shares	0	-3	0	0	0	0	0
Capital measures	0	0	0	0	0	0	0
Other	-47	-29	0	0	0	0	0
Net cash provided by financing activities [3]	-62	58	211	201	-22	-41	-41
Change in liquid funds [1]+[2]+[3]	-29	66	280	253	126	-21	74
Effects of exchange-rate changes on cash	0	-1	0	0	0	0	0
Cash and cash equivalent at end of period	80	145	425	508	372	351	425

Financial Ratios


	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	-21	-73	-154	-105	-12	20	115
Free Cash Flow / Sales	-2.1 %	-4.6 %	-6.2 %	-2.8 %	-0.2 %	0.4 %	2.1 %
Free Cash Flow Potential	79	146	580	217	171	168	243
Free Cash Flow / Net Profit	-102.9 %	-269.0 %	-34.3 %	1547.1 %	23.8 %	-29.5 %	4695.7 %
Interest Received / Avg. Cash	1.6 %	3.5 %	4.2 %	6.0 %	0.3 %	0.3 %	0.3 %
Interest Paid / Avg. Debt	6.5 %	9.7 %	5.5 %	9.4 %	2.1 %	2.1 %	2.1 %
Management of Funds							
Investment ratio	0.0 %	1.8 %	1.9 %	2.2 %	1.7 %	1.5 %	1.5 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	0.0 %	28.3 %	40.0 %	45.7 %	41.5 %	38.4 %	37.7 %
Avg. Working Capital / Sales	11.4 %	9.2 %	8.4 %	6.7 %	5.8 %	6.2 %	6.4 %
Trade Debtors / Trade Creditors	88.5 %	92.5 %	65.0 %	60.8 %	60.8 %	60.8 %	60.8 %
Inventory Turnover	4.6 x	4.8 x	3.7 x	4.3 x	4.5 x	4.5 x	4.5 x
Receivables collection period (days)	62	68	50	45	45	45	45
Payables payment period (days)	114	119	121	115	115	115	115
Cash conversion cycle (Days)	26	25	26	15	11	11	12

CAPEX and Cash Flow


in EUR m



Free Cash Flow Generation



Working Capital



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All **data and consensus estimates** have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 4- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 5- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 6c- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.
- 7-

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Mutares	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A2NB650.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	151	73
Hold	45	22
Sell	7	3
Rating suspended	4	2
Total	207	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	42	86
Hold	5	10
Sell	0	0
Rating suspended	2	4
Total	49	100

PRICE AND RATING HISTORY MUTARES AS OF 11.08.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemier +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Fabio Hölscher +49 40 309537-240
Automobiles, Car Suppliers fhoelscher@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate, Construction pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Hannes Müller +49 40 309537-255
Software, IT hmueller@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate, Telco sstippig@warburg-research.com

Cansu Tatar +49 40 309537-248
Cap. Goods, Engineering ctatar@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Marc Niemann +49 40 3282-2660
Head of Equity Sales, Germany mniemann@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Lea Bogdanova +49 69 5050-7411
United Kingdom, Ireland lbogdanova@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom mfritsch@mmwarburg.com

Maximilian Martin +49 69 5050-7413
Austria, Poland mmartin@mmwarburg.com

Rudolf Alexander Michaelis +49 40 3282-2649
Germany rmichaelis@mmwarburg.com

Roman Alexander Niklas +49 69 5050-7412
Switzerland rniklas@mmwarburg.com

Charlotte Wernicke +49 40 3282-2669
Roadshow/Marketing cwernicke@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

SALES TRADING

Oliver Merkel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Rico Müller +49 40 3282-2685
Sales Trading rmueller@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

DESIGNATED SPONSORING

Marcel Magiera +49 40 3282-2662
Designated Sponsoring mmagiera@mmwarburg.com

Sebastian Schulz +49 40 3282-2631
Designated Sponsoring sschulz@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Designated Sponsoring jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

Refinitiv www.refinitiv.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com